Jane Street’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Jane Street’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-984	Closed	-$6.62K	–	10335
2023 Q4	$6.62K	Buy	984 +493	+100%	+$4.33K	﹤0.01%	9000
2023 Q3	$4.49K	Sell	491 -716	-59%	-$14.4K	﹤0.01%	8449
2023 Q2	$25.5K	Sell	1,207 -682	-36%	-$21K	﹤0.01%	8331
2023 Q1	$50.8K	Buy	1,889 +1,429	+311%	+$66.5K	﹤0.01%	8445
2022 Q4	$16.3K	Buy	+460	New	+$55.3K	﹤0.01%	8654
2022 Q3	–	Sell	-873	Closed	-$165K	–	10701
2022 Q2	$165K	Buy	+873	New	+$176K	﹤0.01%	8339
2022 Q1	–	Sell	-3,042	Closed	-$481K	–	11236
2021 Q4	$474K	Buy	3,042 +790	+35%	+$153K	﹤0.01%	7363
2021 Q3	$451K	Buy	+2,252	New	+$535K	﹤0.01%	7490
2019 Q1	–	Sell	-375	Closed	-$114K	–	5796
2018 Q4	$114K	Buy	+375	New	+$121K	﹤0.01%	4605

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

AWP

Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Jane Street's EIGR Position: Q1 2024 in Review

Jane Street sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 984 shares — an estimated $6.62K sold.

Jane Street first reported a position in EIGR in Q4 2018 and held it in 9 quarters. The position peaked at $474K in Q4 2021. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

Jane Street reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Jane Street sold 984 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $6.62K.
Jane Street first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 9 quarters.
Jane Street's Eiger BioPharmaceuticals, Inc. position peaked at $474K in Q4 2021.
24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Jane Street's 13F filing for Q1 2024, filed 16 May 2024.